Cone-Rod Dystrophy clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

    open to eligible people ages 18 years and up

    This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

    San Francisco, California and other locations

Our lead scientists for Cone-Rod Dystrophy research studies include .

Last updated: